Jump to main content
Jump to site search


Ru(II)–thyminate complexes: new metallodrug candidates against tumor cells

Author affiliations

Abstract

Herein, we used thymine (HThy) as a ligand to form two new ruthenium(II) complexes with formula [Ru(PPh3)2(Thy)(bipy)]PF6 (1) and [Ru(Thy)(bipy)(dppb)]PF6 (2). The complexes were characterized by spectroscopic, spectrometric and X-ray crystallography analyses. Complexes 1 and 2 can interact with ctDNA presenting binding constants, Kb, of 0.4 and 1.2 × 103 M−1, respectively. Their cytotoxic activities towards tumor cell lines (B16-F10, HepG2, K562 and HL-60) and non-tumor cells (PBMCs) were evaluated using the Alamar blue assay. Complex 1 exhibits high cytotoxicity against tumor cells, showing IC50 values of 0.01 and 1.81 μM against the HL-60 and HepG2 cell lines, respectively. Therefore, compound 1 can be considered as a promising antitumor metallodrug.

Graphical abstract: Ru(ii)–thyminate complexes: new metallodrug candidates against tumor cells

Back to tab navigation

Supplementary files

Publication details

The article was received on 10 Nov 2017, accepted on 24 Mar 2018 and first published on 26 Mar 2018


Article type: Paper
DOI: 10.1039/C7NJ04368F
Citation: New J. Chem., 2018, Advance Article
  •   Request permissions

    Ru(II)–thyminate complexes: new metallodrug candidates against tumor cells

    R. S. Correa, V. Freire, M. I. F. Barbosa, D. P. Bezerra, L. M. Bomfim, D. R. M. Moreira, M. B. P. Soares, J. Ellena and A. A. Batista, New J. Chem., 2018, Advance Article , DOI: 10.1039/C7NJ04368F

Search articles by author

Spotlight

Advertisements